There’s a massive biotech buyout underway, with Biogen paying over $6 billion to bulk up its rare disease portfolio. We’ll explore the “arms race” brewing in big pharma.

Plus, we have more ‘power players’ joining the show. Valley Bank’s CEO gives us a read on rising rates and new bank rules, while the Union Square Hospitality Group CEO gives us insight into the consumer.